JP2002513768A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002513768A5 JP2002513768A5 JP2000546792A JP2000546792A JP2002513768A5 JP 2002513768 A5 JP2002513768 A5 JP 2002513768A5 JP 2000546792 A JP2000546792 A JP 2000546792A JP 2000546792 A JP2000546792 A JP 2000546792A JP 2002513768 A5 JP2002513768 A5 JP 2002513768A5
- Authority
- JP
- Japan
- Prior art keywords
- gdf
- pharmaceutical preparations
- inhibitor
- individuals
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010056852 Myostatin Proteins 0.000 description 13
- 102000004472 Myostatin Human genes 0.000 description 12
- 239000000825 pharmaceutical preparation Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010006769 Monosaccharide Transport Proteins Proteins 0.000 description 1
- 102000005455 Monosaccharide Transport Proteins Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108091006296 SLC2A1 Proteins 0.000 description 1
- 108091006300 SLC2A4 Proteins 0.000 description 1
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 1
- 102100033939 Solute carrier family 2, facilitated glucose transporter member 4 Human genes 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8449098P | 1998-05-06 | 1998-05-06 | |
| US60/084,490 | 1998-05-06 | ||
| PCT/US1999/010089 WO1999056768A1 (en) | 1998-05-06 | 1999-05-06 | Methods for treating diabetes by inhibiting gdf-8 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002513768A JP2002513768A (ja) | 2002-05-14 |
| JP2002513768A5 true JP2002513768A5 (cg-RX-API-DMAC7.html) | 2006-07-06 |
| JP4544742B2 JP4544742B2 (ja) | 2010-09-15 |
Family
ID=22185291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000546792A Expired - Lifetime JP4544742B2 (ja) | 1998-05-06 | 1999-05-06 | Gdf−8の阻害による糖尿病の処置法 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US6368597B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1075272B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4544742B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU765214B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2331410C (cg-RX-API-DMAC7.html) |
| DE (1) | DE69941116D1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2330062T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999056768A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| ES2330062T3 (es) * | 1998-05-06 | 2009-12-03 | Metamorphix, Inc. | Procedimientos para tratar la diabetes por inhibicion de gdf-8. |
| TWI329129B (en) * | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7510851B2 (en) * | 2001-12-17 | 2009-03-31 | Metabolex, Inc. | Compositions and methods for diagnosing and treating diabetes, insulin resistance and dyslipidemia |
| BR0307907A2 (pt) | 2002-02-21 | 2011-07-05 | Wyeth Corp | gasp1: proteìna contendo domìnio de folistatina |
| PL374966A1 (en) | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
| US6908632B1 (en) | 2002-04-19 | 2005-06-21 | Pharmanex, Llc | Blood glucose modulating compositions and methods |
| AU2003267246A1 (en) * | 2002-09-16 | 2004-04-30 | The Johns Hopkins University | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| AU2003297460A1 (en) * | 2002-12-19 | 2004-07-14 | Scios, Inc. | TREATMENT OF OBESITY AND ASSOCIATED CONDITIONS WITH TGF-Beta INHIBITORS |
| AU2003301195B2 (en) * | 2002-12-20 | 2010-01-07 | Amgen Inc. | Binding agents which inhibit myostatin |
| WO2004108157A2 (en) | 2003-06-02 | 2004-12-16 | Wyeth | Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders |
| WO2005066204A2 (en) * | 2003-12-31 | 2005-07-21 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| CA2558478A1 (en) * | 2004-03-02 | 2005-09-15 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors and uses thereof |
| US20070178095A1 (en) * | 2004-03-23 | 2007-08-02 | Eli Lilly And Company | Anti-myostatin antibodies |
| MX2007000976A (es) * | 2004-08-12 | 2007-04-10 | Wyeth Corp | Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion. |
| MX2007008132A (es) * | 2004-12-30 | 2007-07-20 | Schering Plough Ltd | Vacuna para aumentar el crecimiento basada en epitopes neutralizantes. |
| EP1864139A2 (en) * | 2005-03-23 | 2007-12-12 | Wyeth | Detection of an immune response to gdf-8 modulating agents |
| CA2538208A1 (en) * | 2005-05-04 | 2006-11-04 | Universite Laval | Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease |
| US7888486B2 (en) | 2005-08-19 | 2011-02-15 | Wyeth Llc | Antagonist antibodies against GDF-8 |
| KR101135220B1 (ko) * | 2005-10-06 | 2012-04-24 | 일라이 릴리 앤드 캄파니 | 항-마이오스타틴 항체 |
| UA92504C2 (en) * | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| US20070149458A1 (en) * | 2005-12-06 | 2007-06-28 | Amgen Inc. | Uses of myostatin antagonists |
| HRP20130320T1 (en) * | 2006-09-05 | 2013-05-31 | Eli Lilly And Company | Anti-myostatin antibodies |
| KR20120023787A (ko) | 2009-05-22 | 2012-03-13 | 가부시키가이샤 에리나 | 대사증후군의 예방제 및/또는 치료제 |
| WO2011087946A1 (en) | 2010-01-15 | 2011-07-21 | Rigel Pharmaceuticals, Inc. | Screening assay employing dex and gdf8 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| PH12013500315A1 (en) | 2010-08-16 | 2013-04-29 | Amgen Inc | Antibodies that bind myostatin, compositions and methods |
| SMT201800092T1 (it) | 2011-11-14 | 2018-03-08 | Regeneron Pharma | Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a |
| MY177331A (en) * | 2012-06-15 | 2020-09-12 | Pfizer | Improved antagonist antibodies against gdf-8 and uses therefor |
| RS58801B1 (sr) | 2012-09-13 | 2019-07-31 | Bristol Myers Squibb Co | Skafold domenski proteini na bazi fibronektina koji se vezuju za miostatin |
| HRP20201914T1 (hr) | 2013-05-06 | 2021-01-22 | Scholar Rock, Inc. | Sastavi i postupci za modulaciju faktora rasta |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素a之抗體及其用途 |
| CN104931327B (zh) * | 2015-03-24 | 2018-10-19 | 重庆医科大学 | 微米级生物材料石蜡切片方法 |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| IL276921B2 (en) | 2018-03-01 | 2025-12-01 | Regeneron Pharma | Methods for altering body composition |
| WO2020075845A1 (ja) * | 2018-10-12 | 2020-04-16 | シーシーアイホールディングス株式会社 | クラスiのグルコーストランスポーター(glut)の発現誘導剤、並びにこれを用いた医薬組成物および飲食品組成物 |
| CN110408616B (zh) * | 2019-07-09 | 2021-06-15 | 中南民族大学 | GLUT4基因敲除的sgRNA、A549细胞系及其构建方法 |
| KR20220054608A (ko) | 2019-09-03 | 2022-05-03 | 노파르티스 아게 | ActRII 수용체 길항제를 포함하는 간 질환 또는 장애 치료제 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6162896A (en) * | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| US5994618A (en) * | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| CA2157577C (en) * | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
| US6465239B1 (en) * | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
| AU6274298A (en) | 1997-02-05 | 1998-08-25 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-8 |
| WO1999006559A1 (en) * | 1997-08-01 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (gdf) receptors |
| US6696260B1 (en) * | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| ES2330062T3 (es) * | 1998-05-06 | 2009-12-03 | Metamorphix, Inc. | Procedimientos para tratar la diabetes por inhibicion de gdf-8. |
| EE200200025A (et) * | 1999-07-20 | 2003-04-15 | Pharmexa A/S | Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto |
-
1999
- 1999-05-06 ES ES99925578T patent/ES2330062T3/es not_active Expired - Lifetime
- 1999-05-06 DE DE69941116T patent/DE69941116D1/de not_active Expired - Lifetime
- 1999-05-06 CA CA002331410A patent/CA2331410C/en not_active Expired - Lifetime
- 1999-05-06 EP EP99925578A patent/EP1075272B1/en not_active Expired - Lifetime
- 1999-05-06 US US09/305,989 patent/US6368597B1/en not_active Expired - Lifetime
- 1999-05-06 AU AU41832/99A patent/AU765214B2/en not_active Ceased
- 1999-05-06 WO PCT/US1999/010089 patent/WO1999056768A1/en not_active Ceased
- 1999-05-06 JP JP2000546792A patent/JP4544742B2/ja not_active Expired - Lifetime
-
2001
- 2001-11-19 US US09/988,835 patent/US20020031517A1/en not_active Abandoned
-
2005
- 2005-06-16 US US11/155,336 patent/US20060121035A1/en not_active Abandoned
-
2008
- 2008-02-14 US US12/070,067 patent/US9150643B2/en not_active Expired - Fee Related
-
2015
- 2015-08-28 US US14/838,490 patent/US20160122424A1/en not_active Abandoned
-
2017
- 2017-08-24 US US15/685,582 patent/US20180134779A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004503598A5 (cg-RX-API-DMAC7.html) | ||
| JP2002527727A5 (cg-RX-API-DMAC7.html) | ||
| IL170685A0 (en) | Protein conjugate | |
| WO2002015920A3 (en) | Treatment of hyperproliferative diseases | |
| MX353044B (es) | Liberacion sostenida de anti-infecciosos. | |
| ES2178228T3 (es) | Cepas fungicas para la expresion de proteinas. | |
| Kay et al. | Enhancement of human lymphocyte natural killing function by non-opioid fragments of β-endorphin | |
| CA2330183A1 (en) | Novel insulin analogs with enhanced zinc binding | |
| RU2004114865A (ru) | Композиция и способ лечения диабета | |
| WO2000066173A3 (en) | Targeting of infectious agents bearing host cell proteins | |
| Morimoto et al. | Photosensitivity from pyridoxine hydrochloride (vitamin B6) | |
| RU2005118425A (ru) | Цитомодуляторные пептиды для лечения интерстициального цистита | |
| Kleinbloesem et al. | Pharmacokinetics and bioavailability of percutaneous ibuprofen. | |
| JP2004520009A5 (cg-RX-API-DMAC7.html) | ||
| JP2002201141A5 (cg-RX-API-DMAC7.html) | ||
| WO2001054707A3 (de) | Veränderung von oberflächenproteomem durch aminopeptidase-inhibitoren | |
| Witte et al. | Tolerance and pharmacodynamics of the angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S, 3S, 5S)-2-azabicyclo [3.3. 0] octane-3-carboxylic acid (Hoe 498) in healthy volunteers. | |
| CA2322055A1 (fr) | Nouvelle famille de canaux potassium de mammiferes mecanosensibles et actives par les acides gras polyinsatures et leur utilisation notamment pour le criblage de drogues | |
| WO2001075095A1 (fr) | Procede de production de proteine de recombinaison | |
| BR0009636B1 (pt) | processo para a preparação de insulina madura ou um derivado de insulina madura. | |
| Smith et al. | Once-daily monotherapy with trandolapril in the treatment of hypertension. | |
| JP2004505635A5 (cg-RX-API-DMAC7.html) | ||
| CA2241941A1 (en) | Therapeutic agent containing .omega.-feline interferon for treating feline aids virus infections and feline atopic dermatitis | |
| Green et al. | The disposition of four tetracyclines in normal subjects | |
| Enyeart et al. | Reciprocal modulation of voltage-gated and background K+ channels mediated by nucleotides and corticotropin |